PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.
暂无分享，去创建一个
R. Bernards | N. Schultz | C. Sotiriou | S. Loi | J. Baselga | N. Harbeck | P. Nuciforo | M. Piccart-Gebhart | H. Eidtmann | D. Fumagalli | L. de la Peña | E. de Azambuja | I. Majewski | C. Aura | L. Mittempergher | A. Bosma | L. Prudkin | C. Ellis | E. Holmes | J. Jiménez | Maria Carmen Díaz-Delgado